Clinical Trials Logo

Essential Hypertension clinical trials

View clinical trials related to Essential Hypertension.

Filter by:

NCT ID: NCT01848873 Recruiting - Clinical trials for Essential Hypertension

Efficacy of Amlodipine-folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine

Start date: January 2013
Phase: Phase 2/Phase 3
Study type: Interventional

To evaluate the efficacy of Amlodipine-folic Acid Tablets on reduction of blood pressure and plasma homocystein.

NCT ID: NCT01825759 Recruiting - Clinical trials for Coronary Heart Disease

Danshen Dropping Pill for Coronary Heart Disease Heart and Artery Structure and Function

Start date: January 2013
Phase: Phase 4
Study type: Interventional

The Impact of Compound danshen dropping pill for coronary heart disease (CHD) heart and artery structure and function in patients with hypertension

NCT ID: NCT01742702 Recruiting - Aortic Stenosis Clinical Trials

HaemoDYNAMICs in Primary and Secondary Hypertension

DYNAMIC
Start date: May 25, 2006
Phase:
Study type: Observational

The primary aim of the present study was to examine the haemodynamic changes in primary hypertension and secondary hypertension (renal diseases, endocrine diseases, obesity-associated hypertension) with a non-invasive haemodynamic measurement protocol utilizing radial pulse wave analysis and whole-body impedance cardiography in both supine position and during head-up tilt. For comparison, haemodynamics of subjects with chronic fatigue syndrome will also be recorded.

NCT ID: NCT01629225 Recruiting - Clinical trials for Essential Hypertension

GRK4 Polymorphisms Blood Pressure Response to Candesartan

Start date: July 2013
Phase: Phase 4
Study type: Interventional

The purpose of this study is to investigate the association between GRK4 polymorphisms and essential hypertension in southwestern Han Chinese and test whether these polymorphisms were associated with the changes in blood pressure in patients with essential hypertension treated with angiotensin II Type antagonist candesartan.

NCT ID: NCT01617551 Recruiting - Clinical trials for Essential Hypertension

Effect of Renal Denervation on NO-mediated Sodium Excretion and Plasma Levels of Vasoactive Hormones

RENO
Start date: March 2012
Phase: N/A
Study type: Interventional

Catheter based renal denervation (CRD) in humans represents a promising new treatment of resistant hypertension. CRD is currently investigated as a treatment option in patients with resistant hypertension defined as at least 3 antihypertensive drugs (including a diuretic) in a randomized, sham-controlled, multicenter trial in Denmark (ReSet). In ReSet, patients are randomized to either CRD or a sham procedure with 6 months follow up. The mechanisms by which CRD reduce blood pressure are only partly understood and the interaction between renal sympathetic nerves and nitric oxide (NO) has not been investigated in humans. To Study the interaction between NO and renal sympathetic nerves, we designed the present substudy, where the effects of NO-inhibition on renal, hemodynamic and hormonal variables are studied before and after CRD.

NCT ID: NCT01417221 Recruiting - Clinical trials for Essential Hypertension

Renal Sympathetic Modification in Patients With Essential Hypertension

Start date: August 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to observe the incident of composite cardiovascular events after renal sympathetic modification using THERMOCOOL® catheter in patients with essential hypertension, and evaluate safety and efficacy of the intervention.

NCT ID: NCT01413048 Recruiting - Clinical trials for Essential Hypertension

Clinical Trial to Evaluate the Antihypertensive Effect of AGSCT101 in Patient With Hypertension

Start date: January 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the antihypertensive effect of AGSCT101 tablet in patient with stage 1 to 2 essential hypertension.

NCT ID: NCT01011660 Recruiting - Clinical trials for Essential Hypertension

Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients

CHIEF
Start date: October 2007
Phase: Phase 4
Study type: Interventional

The aim of the study is to investigate the optimized treatment strategy of hypertension, so as to make more patients to reach the blood pressure goals and to reduce cardio-cerebrovascular events. Objective and Methods: Patients are eligible for inclusion in the study if they are essential hypertension, 50-79 years of age with at least one cardiovascular risk factor and sign the informed consent forms. This project is a multi-centre, prospective randomized,,openlabel blind-endpoint evaluation controlled (PROBE) trial. 12000 patients will be randomly assigned to either of low-dose Amlodipine+Telmisartan group or Amlodipine+ diuretics group. Among those patients with serum cholesterol between 4.0-6.1mmol/L, they will be also randomized into small dose of statin-based regimen or standard management regimen; Patients will also randomly assigned to intensive lifestyle intervention group or standard intervention group according to the community area where the patients in.

NCT ID: NCT00994617 Recruiting - Clinical trials for Essential Hypertension

Monotherapy Versus Dual Therapy for Initial Treatment for Hypertension

Pathway 1
Start date: January 2010
Phase: Phase 4
Study type: Interventional

To test whether the current custom of initiating treatment for hypertension with a single drug is less effective in the short-term than initial combination therapy, and results in the eventual need for comparatively more antihypertensive drug therapy.

NCT ID: NCT00716950 Recruiting - Clinical trials for Essential Hypertension

Valsartan and Amlodipine Compared to Losartan and Amlodipine in Hypertensive Patients

Start date: July 2008
Phase: Phase 4
Study type: Interventional

Hypertensive patients with moderate hypertension have a risk to develop cardiovascular events of 15-20% over a period of 10 years. It is important to reach quickly the advised target, but often this result can be obtained with a combination therapy. Some evidences demonstrate sartans and calcium channels blockers can be very useful and safe, but it is also important to verify which association can give side effects or give some pharmacokinetic interactions that can negatively influence the clinical combination efficacy.